La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the treatment of acne. It effectively clears existing acne blemishes and penetrates pores to control the formation of acne blemishes. Additionally, it helps prevent the emergence of new acne blemishes.

Dosage and Administration

Healthcare professionals should instruct patients to shake the product well before use. Prior to application, the skin must be cleaned thoroughly to ensure optimal efficacy. A thin layer of the product should be applied to the entire affected area one to three times daily, depending on the patient's needs and the physician's recommendations.

It is advisable to initiate treatment with one application per day to minimize the risk of excessive skin drying. Based on the patient's response, the frequency may be gradually increased to two or three times daily. Should the patient experience bothersome dryness or peeling, the application frequency should be reduced to once daily or every other day.

For patients who will be exposed to sunlight, it is essential to apply sunscreen after using this product. In cases where irritation or sensitivity occurs, the use of both the product and sunscreen should be discontinued, and the patient should consult a physician for further guidance.

Contraindications

There are no specific contraindications identified for this product. However, it is advised that if the product is swallowed, medical assistance should be sought immediately or contact a Poison Control Center.

Additionally, concurrent use of another topical acne medication may heighten the risk of skin irritation and dryness. In cases of irritation, it is recommended to limit use to one topical acne medication at a time.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to seek emergency medical assistance immediately if the product is ingested, or to contact a Poison Control Center without delay.

It is important to note that the concurrent use of this product with other topical acne medications may increase the risk of skin irritation and dryness. To minimize the potential for adverse effects, patients should be instructed to use only one topical acne medication at a time. If irritation occurs, discontinuation of the product and consultation with a healthcare provider is recommended.

No specific laboratory tests are required for monitoring the safe use of this product. However, healthcare professionals should remain vigilant for any signs of adverse reactions in patients using this medication.

Side Effects

For external use only. No specific adverse reactions have been reported in clinical trials or postmarketing experiences. Patients should be advised to adhere strictly to the intended use to minimize any potential risks associated with improper application.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily. Care should be taken to observe for signs of excessive drying of the skin. If bothersome dryness or peeling occurs, the application frequency should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of salicylic acid during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to potential risks to the fetus, including the possibility of teratogenic effects associated with its use. Pregnant women should avoid using this product unless directed by a healthcare provider. It is essential for healthcare professionals to counsel women of childbearing potential regarding these risks and to consider alternative treatments when necessary.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose effectively.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for appropriate treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication concurrently with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance is essential for ensuring the safe and effective use of the medication.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, maintaining a range of 68°F to 77°F (20°C to 25°C). Additionally, the product must be protected from freezing to ensure its integrity and efficacy. Proper handling and storage conditions are crucial for maintaining the quality of the product throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)